The rise of Viagra initially drove a boom for the drug industry, but recent developments present a complicated scenario for shareholders. Generic versions are reducing revenue, and ongoing litigation add more risk to https://nanabcxy306520.mpeblog.com/74347918/the-blue-pill-and-big-pharma-a-risky-investment